Clotting drug may replace plasma transfusions in heart surgery

NCT ID NCT04244981

Terminated Disease control Sponsor: SHI Jia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not completed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prothrombin Complex Concentrate (PCC)
What this could lead to: If it works, this could offer a faster, more standardized way to control bleeding after heart valve surgery, potentially reducing the need for plasma transfusions.
What could go wrong: This trial was terminated early, so results are limited. It is a non-inferiority study, meaning it only aims to show PCC is not worse than plasma, not that it is better. Bleeding risks and side effects like clotting are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC SURGICAL PROCEDURES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart valve disorder hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC SURGICAL PROCEDURES VALVULAR HEART SURGERY

Contacts and locations

Locations

Cardiovascular Institute and Fuwai Hospital, CAMS&PUMC

Beijing, Beijing Municipality, 100037, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.